Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | CEL | P19835 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675644 | 0.99 | DAO (0.41) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670123 | 0.97 | DAO (0.37) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670034 | 0.94 | GPR84 (0.39) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4676115 | 0.92 | GPR84 (0.43) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670460 | 0.92 | GPR84 (0.41) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4675869 | 0.91 | GPR84 (0.45) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670381 | 0.91 | GPR84 (0.36) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670069 | 0.90 | GPR84 (0.41) | DAONFE2L2HPGDGPR84CYP19A1 | |
| SCHEMBL4670058 | 0.85 | PARP15 (0.41) | DAOGPR84 | |
| SCHEMBL4675640 | 0.84 | PARP15 (0.42) | DAOHPGDGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | DAO 3008/4885NFE2L2 2675/4885HPGD 4164/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | DAO 2646/4885NFE2L2 3069/4885HPGD 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.